Curtis K. Johnston, Pharm.D.

Principal Scientist I

Curtis joined Metrum in 2014 after receiving his Pharm.D. from the University at Buffalo and completing a clinical PK/PD Fellowship through UNC Chapel Hill/Quintiles. His clinical experience includes infectious disease (bacterial), oncology, and chronic liver disease (HCV and NASH). Curtis’s research interests include Bayesian methodology and the application of M&S to help inform drug development decisions.

Recent publications by this scientist

Low-Dose Empagliflozin as Adjunct-to-Insulin Therapy in Type 1 Diabetes: A Valid Modeling and Simulation Analysis to Confirm Efficacy

December 19, 2019

Perkins BA, Soleymanlou N, Rosenstock J, Skyler JS, Laffel LM, Liesenfeld KH, Neubacher D, Riggs MM, Johnston CK, Eudy-Byrne RJ, Elmokadem A, George JT, Marquard J, Nock V.  Diabetes, Obesity & Metabolism, 2019 Dec 19. Available from: https://doi.org/10.1111/dom.13945.

View More

M-EASE-2: A Modelling and simulation study conducted to further characterize the efficacy of low-dose Empagliflozin as Adjunctive to inSulin thErapy (M-EASE) in Type 1 Diabetes Mellitus (T1DM)

June 13, 2019

Johnston C, Riggs MM, Marquard J, Soleymanlou N, Nock V, Liesenfeld, K. Poster presented at 2019 Population Approach Group in Europe (PAGE). Stockholm, Sweden. 13 June 2019. Abstract IV-66.

Download PDF

M-EASE-1: A Modelling and simulation study conducted to further characterize the efficacy of low-dose Empagliflozin as Adjunctive to inSulin thErapy (M-EASE) in Type 1 Diabetes Mellitus

June 13, 2019

Eudy-Byrne R, Elmokadem A, Riggs MM, Johnston C, Marquard J, Soleymanlou N, Nock V, Liesenfeld K. Poster presented at 2019 Population Approach Group in Europe (PAGE). Stockholm, Sweden. 13 June 2019. Abstract III-02.

Download PDF